Intravenous tissue plasminogen activator administration in community hospitals facilitated by telestroke service

Neurosurgery

Volumn 73, Issue 4, 2013, Pages 667-671

  Chalouhi, Nohra ^a   Dressler, Jeremy A ^a   Kunkel, Emily S I ^a   Dalyai, Richard ^a   Jabbour, Pascal ^a   Gonzalez, L Fernando ^a   Starke, Robert M ^a   Dumont, Aaron S ^a   Rosenwasser, Robert ^a   Tjoumakaris, Stavropoula ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Stroke; Telemedicine; Telestroke; Thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; COMMUNITY HOSPITAL; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT TRANSPORT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ROBOTICS; STROKE PATIENT; TELECONSULTATION; TELEMEDICINE; UNITED STATES; UNIVERSITY HOSPITAL;

ADMINISTRATION, INTRAVENOUS; FIBRINOLYTIC AGENTS; HOSPITALS, COMMUNITY; HUMANS; REMOTE CONSULTATION; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84885051763     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000073     Document Type: Article

References (29)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125(1):e2-e220.
2. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364-2372.
3. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115(20):e478-e534.
4. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945-2948.
5. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42(7):1952-1955.
6. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing. 2004;33(2):116-121.
7. Demaerschalk BM, Miley ML, Kiernan TE, et al. Stroke telemedicine. Mayo Clin Proc. 2009;84(1):53-64.
8. Jabbour P, Gonzalez LF, Tjoumakaris S, Randazzo C, Rosenwasser R. Stroke in the robotic era. World Neurosurg. 2010;73(6):603-604.
9. Audebert HJ, Kukla C, Clarmann von Claranau S, et al. Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. Stroke. 2005;36(2):287-291.
10. Hess DC, Wang S, Hamilton W, et al. REACH: clinical feasibility of a rural telestroke network. Stroke. 2005;36(9):2018-2020.
11. Switzer JA, Hall C, Gross H, et al. A web-based telestroke system facilitates rapid treatment of acute ischemic stroke patients in rural emergency departments. J Emerg Med. 2009;36(1):12-18.
12. Schwamm LH, Holloway RG, Amarenco P, et al. A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2009;40(7): 2616-2634.
13. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
14. Heuschmann PU, Berger K, Misselwitz B, et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke. 2003;34(5):1106- 1113.
15. Wang S, Lee SB, Pardue C, et al. Remote evaluation of acute ischemic stroke: reliability of National Institutes of Health Stroke Scale via telestroke. Stroke. 2003; 34(10):e188-e191.
16. Schwab S, Vatankhah B, Kukla C, et al. Long-term outcome after thrombolysis in telemedical stroke care. Neurology. 2007;69(9):898-903.
17. Audebert HJ, Schenkel J, Heuschmann PU, Bogdahn U, Haberl RL. Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. Lancet Neurol. 2006;5(9): 742-748.
18. Audebert HJ, Schultes K, Tietz V, et al. Long-term effects of specialized stroke care with telemedicine support in community hospitals on behalf of the Telemedical Project for Integrative Stroke Care (TEMPiS). Stroke. 2009;40(3):902-908.
19. Sairanen T, Soinila S, Nikkanen M, et al. Two years of Finnish Telestroke: thrombolysis at spokes equal to that at the hub. Neurology. 2011;76(13):1145-1152.
20. Nelson RE, Saltzman GM, Skalabrin EJ, Demaerschalk BM, Majersik JJ. The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. Neurology. 2011;77(17):1590-1598.
21. Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ. Costeffectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives. Circ Cardiovasc Qual Outcomes. 2013;6(1):18-26.
22. Silva GS, Farrell S, Shandra E, Viswanathan A, Schwamm LH. The status of telestroke in the United States: a survey of currently active stroke telemedicine programs. Stroke. 2012;43(8):2078-2085.
23. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(8):1015-1020.
24. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke. 2001;32(5):1061-1068.
25. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61(3):346-350.
26. Alberts MJ, Hampel M, Range J, Cantwell V, Troy J, Eggen N. IV TPA administration to eligible patients at Certified primary stroke centers. Stroke. 2012; 43:A193.
27. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med. 2006;31(6 suppl 2):S210-S216.
28. Rogove HJ,McArthur D, Demaerschalk BM, Vespa PM. Barriers to telemedicine: survey of current users in acute care units. Telemed J E Health. 2012;18(1):48-53.
29. Pervez MA, Silva G, Masrur S, et al. Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe. Stroke. 2010;41(1):e18-e24.